Sight Sciences, Inc. (NASDAQ:SGHT) Given Consensus Rating of "Hold" by Analysts

Key Points

• Sight Sciences, Inc. has received a consensus rating of "Hold" from analysts, with four analysts recommending a hold and three suggesting a buy, while the average one-year price target is $4.4167.
• Institutional investors have increased their positions in Sight Sciences, with CWM LLC raising its holdings by 70.2% during the second quarter and several new purchases made by other funds.
• The company reported a negative net margin of 64.23% and earnings per share of ($0.23), exceeding analyst estimates, with revenue reaching $19.56 million for the quarter.

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) has earned an average rating of "Hold" from the seven analysts that are covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $4.4167.

Several research analysts have recently issued reports on the stock. Piper Sandler reiterated a "neutral" rating and issued a $4.00 target price (up previously from $3.50) on shares of Sight Sciences in a research note on Wednesday, June 18th. Morgan Stanley upped their target price on shares of Sight Sciences from $3.00 to $4.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research note on Thursday, August 28th. Wall Street Zen upgraded shares of Sight Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. Finally, Lake Street Capital upgraded shares of Sight Sciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $3.00 to $5.00 in a research note on Friday, August 8th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. CWM LLC raised its holdings in shares of Sight Sciences by 70.2% during the second quarter. CWM LLC now owns 7,607 shares of the company's stock valued at $31,000 after purchasing an additional 3,137 shares during the last quarter. ProShare Advisors LLC purchased a new position in shares of Sight Sciences during the fourth quarter valued at approximately $36,000. Tower Research Capital LLC TRC raised its holdings in shares of Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company's stock valued at $48,000 after purchasing an additional 2,875 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of Sight Sciences during the second quarter valued at approximately $49,000. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in shares of Sight Sciences by 38.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company's stock valued at $66,000 after purchasing an additional 4,453 shares during the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.

Sight Sciences Trading Down 2.6%

Shares of NASDAQ SGHT opened at $3.35 on Thursday. Sight Sciences has a 1 year low of $2.03 and a 1 year high of $6.29. The stock has a market cap of $175.44 million, a P/E ratio of -3.49 and a beta of 2.42. The firm has a 50-day moving average of $3.75 and a 200 day moving average of $3.46. The company has a debt-to-equity ratio of 0.57, a current ratio of 10.01 and a quick ratio of 9.49.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. The business had revenue of $19.56 million during the quarter, compared to analysts' expectations of $18.18 million. Sight Sciences had a negative net margin of 64.23% and a negative return on equity of 59.38%. Sight Sciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Sight Sciences will post -0.99 EPS for the current fiscal year.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.